focus -WSS

focus

author：comprehensive 2025-09-28 01:39:30 - browse：65489

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Readout Newsletter: Zepbound, Valneva's vaccine, and more

WSS

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Healthy food access boosts outcomes in two studies

What is STAT's opinion section for?

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

knowledge

focus

entertainment

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

First transplant of an entire human eye performed

Drug repurposing or repositioning? The language matters

UnitedHealth quietly bought dozens of outpatient centers

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

What health policies could hitch a ride on a spending bill?

In age of alternative facts, a scholarly course on calling out crap

Ohio still needs to do more to protect the right to abortion

knowledge

Precocious puberty in girls comes with mental health risks

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Air quality improving but still lags in Black, Hispanic communities

Experimental asthma app from Apple and Anthem shows promise

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

knowledge

leisure time

explore

hotspot